Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Looking for the Next Dendreon? Consider Oncothyreon
- VFC submits: Dendreon DNDN shocked the investing world last month after reporting positive Phase III results for it's prostate cancer immunotherapy treatment Provenge. Although the company still must overcome the hurdle of FDA approval, investors are out searching for the next Dendreon, and VFC's Stock House, as always, is...
- External links 2009-05-17
- Will Insmed's IPLEX Meet Expectations?
- VFC submits: Insmed Inc INSM released its first quarter results last week, which included a $130 million payment from Merck MRK that completed the sale of Insmed's Follow-on-Biologics (FOB) platform which was agreed to in February. Since news of the sale was announced, INSM has inched higher from the...
- External links 2009-05-18
- Epicept May Have Potential, But How Long are Investors Willing to Wait?
- VFC submits: When the European Commission decided to approve Ceplene last October, Epicept EPCT looked to be as safe an investment as any since the only thing that stood in the way of Epicept and a revenue stream was the search for a marketing partner. Now, seven months later,...
- External links 2009-05-22
- Stock Watch: Contrary Indicator on Antigenics
- VFC submits: Antigenics AGEN became owner of the world's first approved cancer vaccine last April when Oncophage, the company's immunotherapy treatment for kidney cancer, was granted approval in Russia.Since then, investors have been waiting for additional news to spark the share price of the company, and that news may...
- External links 2009-05-27
- Vanda Pharmaceuticals: A Biotech Stock Worth Watching
- VFC submits: During Tuesday's broad market rally, the action of a few stocks caught my attention and are worth watching for at least the rest of the week.Vanda Pharmaceuticals VNDA: by VFC's Stock House
- External links 2009-05-27
- Titan Pharmaceuticals' Story Is Just Beginning
- VFC submits: Titan Pharmaceuticals (TTNP.PK) rose another 25%, and may still rise further, after the recent FDA approval of Fanapt. Fanapt, produced by Vanda Pharmaceuticals VNDA to treat schizophrenia, is Titan's licensed product from which it will receive royalty payments of between 8%-10% from net sales of the product....
- External links 2009-05-27
- Antigenics' Contrary Indicator
- VFC submits: Shares of Antigenics AGEN dropped on high volume earlier this week and I posted here that I thought that was a contrary indicator pending significant news that would soon be released.On Wednesday, the company filed a form 8k with the SEC that executes a letter of intent...
- External links 2009-05-29
- Epicept: How Long Will Investors Wait?
- VFC submits: Shares of Epiecept EPCT rose nearly 15% in early trading on Thursday after the company released news regarding its early stage anti-tumor agent Crinobulin. The full results of an already completed Phase I trial will be presented at the annual American Society of Clinical Oncology ASCO meeting...
- External links 2009-05-29
- BVTI Rises on Positive Phase III Results for BiovaxID
- VFC submits: Shares of Biovest International Inc (BVTI.PK) opened the week significantly higher on news that the company's investigational cancer vaccine, BiovaxID, extended the lives of patients treated for follicular non-Hodgkin’s lymphoma.According to the data presented at the American Society of Clinical Oncology’s annual meeting this weekend, patients who...
- External links 2009-06-02
- Epicept Still Searching for Partner to Help Launch Its Latest Drug
- VFC submits: Epicept Corporation EPCT announced on Tuesday that a partner has been found for Ceplene, the company's drug that is approved in the European Union for maintenance therapy for adult patients with AML in first remission. However, the partnership agreement is not in preparation for the commercial launch...
- External links 2009-06-03
- Stock Watch: Biodelivery Sciences Has Nearly Tripled Over Past Months
- VFC submits: BDSI Sets 52-Week HighStock Watch: BDSIStocks on the Move: BDSIVFC's 2009 Stock Picks, Part IIIBiodelivery Sciences BDSI set a new 52-week high of six dollars during trading on Tuesday and closed not too far off that mark at $5.93. by VFC's Stock House
- External links 2009-06-03
- Antigenics: Rallying Cancer Vaccine Stock
- VFC submits: AGEN's Contrary IndicatorAGEN Stock WatchEarly last week Antigenics' AGEN stock dropped 13% on fairly heavy volume before rebounding in the days leading up to the American Society of Clinical Oncology (ASCO) annual meeting that took place in Orlando, Florida this past weekend. by VFC's Stock House
- External links 2009-06-03
- EpiCept Trading on High Volume
- VFC submits: Three days ago I wrote that Epicept EPCT was a stock worth watching as the company signed a partner to distribute Ceplene in a world wide named patient program.The news that Ceplene, Epicept's drug that is intended to prevent leukemia relapse in patients with Acute Myeloid Leukemia...
- External links 2009-06-05
- Insmed Stock Rising on High Volume, But Still a Good Buy
- VFC submits: Based on the volatility of the stock that has been accompanied by days of high trading volume, I've been predicting for weeks now that Insmed INSM was gearing up to release some significant news, most likely regarding the preliminary data collected from a Phase II trial measuring...
- External links 2009-06-08
- Antigenics: A Gift at $2
- VFC submits: After soaring from sixty cents to over three dollars per share in the timespan of a few days, Antigenics AGEN was trading for under two dollars during early training on Monday morning.Drops such as this one tend to induce a fair amount of selling from 'weak hands',...
- External links 2009-06-08
- CEL-SCI: A Great Buy Looking for Attention
- VFC submits: Cel Sci Corp CVM on Tuesday released yet another announcement regarding their L.E.A.P.S. technology and its possible ability to treat or prevent the Swine Flu.According to the PR, the company by VFC's Stock House
- External links 2009-06-10
- Antigenics: Long Play with a Shot of Potential
- VFC submits: Investors of Antigenics Inc. AGEN expecting big news from Wednesday's shareholder meeting were mostly disappointed with the fact that the conference call was just a rehash of recent events and was not the stage for a significant announcement. However, those who were disappointed by the lack of...
- External links 2009-06-11
- Biodelivery Investors Await FDA Approval, Hope for Surge in Stock Price
- VFC submits: The Food and Drug Administration [FDA] was due to issue an approval decision regarding Biodelivery Science's BDS treatment for pain in cancer patients, Onsolis, by June 15th, but a Monday morning press release issued by the company stated that the FDA decision has been delayed. However, the...
- External links 2009-06-15
- BioDelivery Sciences: Insider Selling Won't Scare Me Away
- VFC submits: A lot has been made of the large number of recent insider sells at BioDelivery Sciences BDSI who, as we know, received notification from the FDA of a minor delay in the pending approval decision for BioDelivery's treatment for pain in cancer patients, Onsolis. I usually take...
- External links 2009-06-24
- Antigenics: Why I Couldn't Resist Buying on the Dip
- VFC submits: In mid-day trading on Tuesday, shares of Antigenics AGEN dropped over 15% and in keeping with my mode of accumulation by buying on the dips, I pulled the trigger and added at $1.66. The stock dropped lower after my trade, but as I've noted here before, AGEN...
- External links 2009-06-24
- << Previous
- page 1 of 4
- Next >>
